New Company Twelve Bio Aims To Improve On CRISPR Gene-Editing Tech

Cas12a Offers Advantages

 
• By Andrew McConaghie

Venture capital firm Arix is financing the Copenhangen, Denmark-based biotech, which is looking to play its part in the fast-maturing gene-editing field.

DNA helix
Gene-editing: Cas12a's small size, high specificity and ability to target sections of DNA are among its potential advantages over Cas9.

More from Gene Therapies

More from Advanced Therapies